Sharvil Patel, MD, Zydus Cadila (Photo | Express) 
Business

Zydus Cadila unit gets USFDA nod for generic plaque psoriasis treatment drug

The drug will be manufactured at the Zydus group's formulation manufacturing facility at the special economic zone, Ahmedabad, the drug firm noted.

PTI

NEW DELHI: Drug firm Zydus Cadila said it has received approval from the US health regulator to market Apremilast tablets, used to treat plaque psoriasis, in the American market.

The company's US-based subsidiary Zydus Pharmaceuticals (USA) Inc has received final approval from the US Food and Drug Administration (USFDA) to market Apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg in the US market, Zydus Cadila said in a statement.

The company's product is the generic version of Otezla tablets, which are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The drug will be manufactured at the Zydus group's formulation manufacturing facility at the special economic zone (SEZ), Ahmedabad, the drug firm noted.

The group now has 323 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.

In US, Rahul Gandhi says India 'sitting on economic disaster', flags jobs, manufacturing crisis

LeT commander Latief Bhat, last 'active militant' in South Kashmir, killed in Kulgam encounter

JPSC-JSSC Reforms Manch announces fresh stir, says Jharkhand govt 'betrayed' job aspirants

Fake newspaper, real threats: How illegal call centres in Bhopal extorted sarpanches across eight states

SC to hear plea against Italian delegate's anti-govt speech at Bharat Summit on Friday